Literature DB >> 26049945

Current state and limitations of daily oral therapy for treatment.

Daniel A Solomon1, Paul E Sax.   

Abstract

PURPOSE OF REVIEW: We aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy. RECENT
FINDINGS: Current ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden.
SUMMARY: Current treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26049945     DOI: 10.1097/COH.0000000000000165

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  9 in total

1.  Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Authors:  Sarah Lilian Pett; Janaki Amin; Andrejz Horban; Jaime Andrade-Villanueva; Marcelo Losso; Norma Porteiro; Juan Sierra Madero; Waldo Belloso; Elise Tu; David Silk; Anthony Kelleher; Richard Harrigan; Andrew Clark; Wataru Sugiura; Marcelo Wolff; John Gill; Jose Gatell; Martin Fisher; Amanda Clarke; Kiat Ruxrungtham; Thierry Prazuck; Rolf Kaiser; Ian Woolley; Juan Alberto Arnaiz; David Cooper; Jürgen K Rockstroh; Patrick Mallon; Sean Emery
Journal:  Clin Infect Dis       Date:  2016-04-05       Impact factor: 9.079

Review 2.  The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.

Authors:  Frank Maldarelli
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

3.  Measuring sexual behaviour in Malawi: a triangulation of three data collection instruments.

Authors:  Nicola Desmond; Nico Nagelkerke; Wezzie Lora; Effie Chipeta; Mwiza Sambo; Moses Kumwenda; Elizabeth L Corbett; Miriam Taegtemeyer; Janet Seeley; David G Lalloo; Sally Theobald
Journal:  BMC Public Health       Date:  2018-06-28       Impact factor: 3.295

4.  Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.

Authors:  Dirk Schürmann; Deanne Jackson Rudd; Andrea Schaeffer; Inge De Lepeleire; Evan J Friedman; Martine Robberechts; Saijuan Zhang; Yang Liu; Bhargava Kandala; Christian Keicher; Martin Däumer; Jörg Hofmann; Jay A Grobler; S Aubrey Stoch; Marian Iwamoto; Wendy Ankrom
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

5.  Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.

Authors:  Wendy Ankrom; Deanne Jackson Rudd; Andrea Schaeffer; Deborah Panebianco; Evan J Friedman; Charles Tomek; S Aubrey Stoch; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

6.  IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation.

Authors:  Ifeanyi Jude Ezeonwumelu; Edurne García-Vidal; Eudald Felip; Maria C Puertas; Bruna Oriol-Tordera; Lucía Gutiérrez-Chamorro; André Gohr; Marta Ruiz-Riol; Marta Massanella; Bonaventura Clotet; Javier Martinez-Picado; Roger Badia; Eva Riveira-Muñoz; Ester Ballana
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 7.  Nicotinic Acetylcholine Receptors in HIV: Possible Roles During HAND and Inflammation.

Authors:  Coral M Capó-Vélez; Manuel Delgado-Vélez; Carlos A Báez-Pagán; José A Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2018-07-14       Impact factor: 4.231

Review 8.  Lessons Learned From Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?

Authors:  V Kalidasan; Kumitaa Theva Das
Journal:  Front Microbiol       Date:  2020-01-31       Impact factor: 5.640

9.  Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County.

Authors:  Oluwadamilola Jolayemi; Laura M Bogart; Erik D Storholm; David Goodman-Meza; Elena Rosenberg-Carlson; Rebecca Cohen; Uyen Kao; Steve Shoptaw; Raphael J Landovitz
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.